Table 2. Corticosteroid pharmacodynamic biomarkers defined by longitudinal analysis of serum samples from corticosteroid naïve and corticosteroid treated DMD and IBD children.
| Protein name | Pre and post corticosteroid treated DMD (n = 9) | Pre and post corticosteroid treated IBD (n = 11) | Description | ||
|---|---|---|---|---|---|
| CS coefficient | p-value | CS coefficient | p-value | ||
| Decreased by GC | |||||
| MMP12 | −0.75 | <0.001 | −0.41 | ns | Macrophage migration |
| IGFBP2 | −0.65 | <0.001 | −0.54 | 0.03 | Activated T cell proliferation |
| IL22RA2 | −0.52 | 0.003 | −0.67 | 0.05 | T cell mediated inflammation |
| LTa1/b2 | −0.44 | 0.003 | −0.15 | ns | B cell activation |
| CCL22 | −0.37 | <0.001 | −1.04 | <0.001 | T cell migration |
| ANGPT2 | −0.34 | 0.001 | −0.41 | 0.04 | Leukocyte migration |
| ITGa1/b1 | −0.29 | 0.03 | −0.12 | ns | Neutrophil chemotaxis |
| FCER2 | −0.27 | 0.005 | −0.28 | 0.03 | B cell differentiation |
| FGG | −0.24 | ns | −0.71 | 0.05 | Acute inflammation marker |
| LY9 | −0.22 | 0.01 | −0.32 | 0.06 | T cell adhesion to other cells |
| Increased by GC | |||||
| MMP3 | 0.98 | 0.004 | 0.58 | 0.02 | Extracellular matrix degradation |
| LEP | 0.36 | 0.002 | 0.32 | ns | Regulates body fat depot |
| AGT | 0.34 | 0.009 | 0.35 | 0.01 | Blood pressure regulator |
| INS | 0.29 | 0.03 | 0.62 | <0.001 | Regulates glucose levels |
| GHBP | 0.24 | 0.03 | 0.24 | 0.002 | Regulate growth |
| AFM | 0.23 | <0.001 | 0.49 | 0.006 | Involved in insulin resistance |
| PROC | 0.11 | 0.023 | 0.06 | ns | Anti-inflammatory/Cytoprotective |
CS: corticosteroid.